A number of other equities research analysts have also recently weighed in on CRSP. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. Needham & Company LLC restated a buy rating and issued a $84.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 23rd. Canaccord Genuity upped their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a report on Wednesday, November 20th. Roth Capital upped their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Finally, Piper Jaffray Companies restated a buy rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 16th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $78.29.
Shares of CRSP opened at $55.80 on Tuesday. The stock has a market cap of $3.15 billion, a PE ratio of -121.30 and a beta of 3.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a fifty-two week low of $30.75 and a fifty-two week high of $74.00. The firm’s 50-day simple moving average is $57.63 and its two-hundred day simple moving average is $53.03.
In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $465,000. The disclosure for this sale can be found here. Corporate insiders own 21.40% of the company’s stock.
Several large investors have recently bought and sold shares of the company. NEXT Financial Group Inc lifted its position in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares during the period. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics during the third quarter valued at approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Crispr Therapeutics during the fourth quarter valued at approximately $26,000. Webster Bank N. A. bought a new position in Crispr Therapeutics during the fourth quarter valued at approximately $26,000. Finally, Advisory Services Network LLC lifted its position in Crispr Therapeutics by 146.0% during the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock valued at $41,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 50.01% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.